Patient Advocacy Strategies Evolve as Genomic Advances Change Understanding of Cancer

Posted by ALCF Staff on September 8th, 2017
No Comments

The ROS1ders, are throwing their energy behind creating preclinical mouse models and cells lines that will inform drug development efforts and improve understanding of resistance mechanisms for all tumors driven by ROS1 rearrangements. Within the Global ROS1 Research Initiative, ROS1ders can donate their left-over tumor tissue after biopsies and surgeries, which a company called Champions Oncology will use to create patient-derived xenograft mouse models.

Click here to read the full article

Comments are closed.